How Compounded Products Differ From FDA-Approved Drugs

Compounded products differ from FDA-approved drugs because they do not undergo the same premarket review for safety, effectiveness, manufacturing quality, labeling, and product consistency. Compounding can address a legitimate patient-specific need, but a compounded product should not be described as FDA-approved merely because it contains a familiar active ingredient or is prepared by a licensed pharmacy.

The distinction is especially important for peptide-related substances. A compounded peptide formulation may differ from an approved product in its active substance, molecular form, strength, excipients, route of administration, manufacturing controls, stability, and supporting evidence.

Understanding these differences is one part of the evaluation of research peptides, where chemical identity, product quality, evidence strength, regulatory status, and route-specific exposure must be considered separately.

Research-use notice: InStrips products are offered for research and analytical use only. They are not intended to diagnose, treat, cure, or prevent any disease, injury, deficiency, absorption disorder, digestive condition, or medical condition.

What Is a Compounded Drug Product?

A compounded drug product is prepared by combining, mixing, or altering ingredients to meet a particular need. Traditional pharmacy compounding may be appropriate when an available FDA-approved drug cannot meet a patient-specific requirement.

Examples may include situations involving:

• an allergy to an inactive ingredient
• difficulty swallowing an available dosage form
• a clinically necessary strength that is not commercially available
• a need for a different formulation
• a temporary drug shortage under applicable conditions

Compounding is not the same as ordinary large-scale drug manufacturing. The legal conditions differ according to the type of compounder and the statutory framework under which the product is prepared.

What Is an FDA-Approved Drug?

An FDA-approved drug is a specific finished product reviewed through an applicable approval pathway. The review concerns more than the name of its active ingredient.

The approved product generally has defined characteristics involving:

• active ingredient
• strength
• dosage form
• route of administration
• manufacturing process
• quality specifications
• labeling
• proposed use
• supporting evidence

Approval applies to the product described in the reviewed application. It does not automatically extend to every formulation that uses the same or a similarly named ingredient.

Compounded Drugs Are Not FDA-Approved

FDA states that compounded drugs are not FDA-approved. The agency does not perform the same premarket verification of their safety, effectiveness, and quality before they are marketed.

This does not mean that every compounded product is defective or inappropriate. It means that the regulatory assurance is different.

A compounded product may be prepared for a valid clinical reason while still lacking the product-specific FDA approval held by an approved drug.

The Active Ingredient Does Not Determine Approval by Itself

A seller may state that a compounded product contains an ingredient also found in an approved drug. That statement does not make the compounded formulation an approved version of the product.

Differences may involve:

• source of the active substance
• salt or molecular form
• impurity profile
• strength
• inactive ingredients
• release characteristics
• route
• packaging
• storage requirements

The regulatory meaning of an active pharmaceutical ingredient should therefore be separated from the approval status of the finished product containing it.

Product-Specific Evidence Matters

Evidence generated with one product may not describe another product that has a different formulation or route.

A clinical study may use a product with defined:

• manufacturing controls
• chemical specifications
• impurity limits
• dose strength
• release behavior
• administration instructions
• storage conditions

A separately compounded product may not reproduce all of these characteristics.

Sharing an active-ingredient name does not prove pharmaceutical equivalence, bioequivalence, therapeutic equivalence, or comparable safety.

Manufacturing Oversight Differs

FDA-approved drug manufacturers generally operate under current good manufacturing practice requirements designed to support consistent production and quality control.

Qualifying products compounded under Section 503A may be exempt from federal current good manufacturing practice requirements when the statutory conditions are met. State pharmacy requirements and other applicable standards may still govern the activity.

This difference can affect the type and extent of controls applied to:

• facility operations
• process validation
• environmental monitoring
• batch documentation
• supplier qualification
• laboratory testing
• stability programs
• investigation of deviations

An exemption from a particular federal requirement should not be described as proof that quality no longer matters.

Strength and Content Uniformity

An approved product is manufactured to meet defined specifications for strength and uniformity.

A compounded product must also contain the intended amount, but errors or insufficient controls can lead to:

• too much active ingredient
• too little active ingredient
• uneven distribution
• incorrect calculations
• degradation during preparation or storage

For unit-based products such as oral films, content uniformity means more than confirming the total amount placed into a batch. The active substance must also be distributed appropriately among individual units.

Sterility and Contamination

Sterile compounded products require controls that reduce the risk of microbial contamination, endotoxin exposure, and particulate matter.

Failure in sterile processing can cause serious harm even when the active ingredient itself is correctly identified.

Nonsterile products can also be affected by:

• microbial growth
• cross-contamination
• incorrect ingredients
• residual cleaning materials
• unsuitable water quality

Product quality therefore includes the complete preparation process, not only the purity reported for the starting ingredient.

Stability Is Formulation-Specific

A bulk substance may remain stable under one set of storage conditions but degrade after it is combined with water, polymers, buffers, flavoring agents, or other excipients.

Stability can be influenced by:

• temperature
• humidity
• oxygen
• light
• pH
• container closure
• microbial conditions
• ingredient interactions

An expiration date or beyond-use date should be supported by the applicable framework and available information. It should not be inferred solely from the stability of a dry starting material.

Compounding Eligibility Is Not Product Approval

A bulk substance may meet a condition that permits its use in qualifying compounding. That status does not mean FDA has approved every finished product prepared from it.

This difference is central to FDA approval and compounding eligibility, which answer separate regulatory questions.

Compounding eligibility asks whether specified legal conditions may permit the compounding activity. Approval asks whether FDA has reviewed and approved a particular finished drug product.

Patient-Specific Compounding

Section 503A generally centers on compounding based on valid patient-specific prescriptions, subject to the conditions established in federal law.

A compounded product should not be promoted as an ordinary substitute for an approved drug merely because customization is possible.

The clinical rationale may involve a need that cannot be met by the commercially available product. Convenience, marketing preference, or a desire to avoid the approval process does not independently establish that need.

Compounded Products and Drug Shortages

Drug shortages can affect whether certain restrictions on producing products that are essentially copies of commercially available drugs apply in a particular situation.

Shortage-related policies can change as supply conditions change. A product that is eligible for certain shortage-related compounding considerations at one time may not retain that position after FDA determines that the shortage has resolved.

Current official information should be checked rather than relying on an older commercial statement.

Labeling and Promotion

A compounded product should not be promoted in a way that falsely implies FDA approval or equivalence with an approved drug.

Potentially misleading descriptions include claims that a compounded product is:

• FDA-approved
• the same as an approved drug
• a generic version without an applicable approval
• clinically proven based only on another product’s trials
• safer because it is customized
• more effective because it uses a different route

Accurate wording should preserve the distinction among ingredient identity, pharmacy preparation, product-specific evidence, and regulatory approval.

Why Peptide Formulations Require Particular Care

Peptides may be sensitive to synthesis errors, oxidation, deamidation, aggregation, enzymatic degradation, and formulation conditions.

A compounded peptide product may require reliable information about:

• sequence identity
• molecular form
• purity
• strength
• degradation products
• sterility or microbial quality
• release from the dosage form
• route-specific exposure

A high purity result for a bulk powder does not establish that the finished product remains stable, releases the peptide intact, or produces predictable human exposure.

What Compounding Does Not Establish

The fact that a product was compounded does not independently establish:

• FDA approval
• clinical effectiveness
• bioequivalence
• therapeutic equivalence
• appropriate dosage
• long-term safety
• consistent manufacturing quality
• suitability for every patient

Each conclusion requires evidence appropriate to the question being asked.

Final Perspective

Compounded products can serve important patient-specific needs, but they occupy a different regulatory position from FDA-approved drugs. FDA does not review each compounded drug through the standard premarket approval process for safety, effectiveness, and quality.

A shared active-ingredient name does not make two products equivalent. Formulation, strength, route, manufacturing, stability, impurities, release, and supporting evidence may differ substantially.

Accurate comparison requires identifying the exact finished products, explaining the applicable compounding framework, and avoiding claims that turn pharmacy preparation or ingredient familiarity into FDA approval.